Loading...
•
Jun 30, 2022
Immunome Q2 2022 Earnings Report
Reported financial results for the second quarter and provided a corporate update.
Key Takeaways
Immunome reported its Q2 2022 financial results, highlighting its transition into a clinical-stage company with the ongoing Phase 1b study of IMM-BCP-01 and continued progress with its lead oncology candidate, IMM-ONC-01.
Transitioned into a clinical stage company.
Continued to dose patients in Phase 1b study of COVID-19 antibody cocktail, IMM-BCP-01.
Presented data demonstrating retention of neutralizing activity against the BA.4/.5, and BA.2.12.1 subvariants of SARS CoV-2.
Advanced IMM-ONC-01 towards IND submission.
Forward Guidance
The press release includes forward-looking statements regarding Immunome’s beliefs and expectations regarding the advancement of its platform and programs, execution of its regulatory, research, clinical and strategic plans and anticipated upcoming milestones for its platform and programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...